Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2).
Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/
07/10/19 • 31 min
Episode Comments
0.0
out of 5
No ratings yet
eg., What part of this podcast did you like? Ask a question to the host or other listeners...
Post
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/breakpoints-474/4-how-eccmid-2019-went-viral-55218"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to #4 – how eccmid 2019 went viral on goodpods" style="width: 225px" /> </a>
Copy